|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-1-29
|
|
pubmed:abstractText |
Imatinib mesylate is a clinically well-tolerated small molecule inhibitor that exerts selective, dual inhibition of the transforming growth factor beta (TGFbeta) and platelet-derived growth factor (PDGF) pathways. This study was undertaken to test the potential use of imatinib mesylate as an antifibrotic drug for the treatment of dermal fibrosis in systemic sclerosis (SSc).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
pubmed-author:DistlerJörg H WJH,
pubmed-author:DistlerOliverO,
pubmed-author:GayRenate ERE,
pubmed-author:GaySteffenS,
pubmed-author:HauserThomasT,
pubmed-author:HuberLars CLC,
pubmed-author:JüngelAstridA,
pubmed-author:MichelBeat ABA,
pubmed-author:SchettGeorgG,
pubmed-author:Schulze-HorselUrsulaU,
pubmed-author:ZwerinaJochenJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
56
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
311-22
|
|
pubmed:meshHeading |
pubmed-meshheading:17195235-Aged,
pubmed-meshheading:17195235-Animals,
pubmed-meshheading:17195235-Bleomycin,
pubmed-meshheading:17195235-Cell Proliferation,
pubmed-meshheading:17195235-Cell Survival,
pubmed-meshheading:17195235-Cells, Cultured,
pubmed-meshheading:17195235-Disease Models, Animal,
pubmed-meshheading:17195235-Dose-Response Relationship, Drug,
pubmed-meshheading:17195235-Extracellular Matrix,
pubmed-meshheading:17195235-Extracellular Matrix Proteins,
pubmed-meshheading:17195235-Female,
pubmed-meshheading:17195235-Fibroblasts,
pubmed-meshheading:17195235-Fibrosis,
pubmed-meshheading:17195235-Gene Expression,
pubmed-meshheading:17195235-Humans,
pubmed-meshheading:17195235-Membrane Potential, Mitochondrial,
pubmed-meshheading:17195235-Mice,
pubmed-meshheading:17195235-Mice, Inbred C3H,
pubmed-meshheading:17195235-Middle Aged,
pubmed-meshheading:17195235-Piperazines,
pubmed-meshheading:17195235-Protein Kinase Inhibitors,
pubmed-meshheading:17195235-Pulmonary Fibrosis,
pubmed-meshheading:17195235-Pyrimidines,
pubmed-meshheading:17195235-RNA, Messenger,
pubmed-meshheading:17195235-Scleroderma, Systemic,
pubmed-meshheading:17195235-Skin,
pubmed-meshheading:17195235-Specific Pathogen-Free Organisms
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
|
|
pubmed:affiliation |
University of Erlangen-Nuremberg, Erlangen, Germany. joerg.distler@med3.imed.uni-erlangen.de
|
|
pubmed:publicationType |
Journal Article
|
